Botanical species · safety record

Salsola kali

The EFSA Compendium of Botanicals holds 11 constituent measurements and 1 adverse-effect record for Salsola kali. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Salsola kali L.

11Constituent measurements
1Safety records
5Cited sources
0Licensed products (Canada)

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

  • 3,4-dihydroxybenzoic acid2
  • Oxalates2
  • Oxalic acid2
  • P-coumaric acid2
  • Estrone1
  • Salsolidine1
  • Salsoline1

Plant parts

  • Aerial part of plants4
  • Unspecified4
  • Live plants2
  • Roots and other underground parts2

Preparations

  • Solvent extraction5

Effect types

  • Digestive1

Target tissues

  • Digestive: pancreas1

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
3,4-dihydroxybenzoic acidAerial part of plantsSolvent extractionHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)No resolvable identifier
3,4-dihydroxybenzoic acidRoots and other underground partsSolvent extractionHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)No resolvable identifier
EstroneAerial part of plantsGelpermeation, High Performance Thin Layer Chromatography (HPTLC)No resolvable identifier
OxalatesUnspecified≥ 5 PercentNo resolvable identifier
OxalatesUnspecified≤ 15.7 PercentNo resolvable identifier
Oxalic acidUnspecified≤ 10.7 PercentNo resolvable identifier
Oxalic acidUnspecified≥ 2 PercentNo resolvable identifier
P-coumaric acidAerial part of plantsSolvent extractionHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)No resolvable identifier
P-coumaric acidRoots and other underground partsSolvent extractionHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)No resolvable identifier
SalsolidineLive plantsNo resolvable identifier
SalsolineLive plantsNo resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

EffectTarget tissuePlant partPreparationTest organismTest typeSource
DigestiveDigestive: pancreasAerial part of plantsSolvent extractionIn vitroResolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Mathams, R. H., Sutherland, A. K. The oxalate content of some Queensland pasture plants. Queensland journal of agricultural science, 1952, vol. 9, p. 317-34.
  2. Tundis, R., Loizzo, M. R., Statti, G. A., Menichini, F. Inhibitory effects on the digestive enzyme alpha-amylase of three Salsola species (Chenopodiaceae) in vitro . Pharmazie, 2007, vol. 62, no. 6, p. 473-475. DOI
  3. Sokolowska-Krzaczek, Anna., Skalicka-Wozniak, Krystyna., Czubkowska, Katarzyna. VARIATION OF PHENOLIC ACIDS FROM HERB AND ROOTS OF SALSOLA KALI L.. Acta societatis botanicorum poloniae, 2009, vol. 78, no. 3, p. 197-201.
  4. Wassel, G. M., Baghdadi, H. H., El Difrawy, S. M. Phyto-ecdysone from some wild Egyptian Salsola species. Fitoterapia, 1979, vol. 50, no. 2, p. 51-2.
  5. Krylov, Yu. F. Comparative action of Salsola kali alkaloids salsoline and salsolidine. Sb. nauchn. tr., ryzansk. med. inst., 1962, vol. 15, p. 45-9.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue